Serrated Pathway Adenocarcinomas: Molecular and Immunohistochemical Insights into Their Recognition

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Gurzu, Simona ^a   Szentirmay, Zoltan ^b   Toth, Erika ^b   Bara, Tivadar ^a,a   Jung, Ioan ^a  

^a UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYTOKERATIN 20; CYTOKERATIN 7; K RAS PROTEIN; PROTEIN MLH1; PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; ASCENDING COLON; BRAF GENE; CANCER STAGING; COLORECTAL CARCINOMA; CONTROLLED STUDY; DESCENDING COLON; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; PROTEIN EXPRESSION; RECTUM; SERRATED PATHWAY ADENOCARCINOMA;

EID: 84874586909     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057699     Document Type: Article

References (19)

1. Longacre TA, Fenoglio-Preiser CF, (1990) Mixed hyperplastic adenomatous polyps/serrated adenomas. A distinct form of colorectal neoplasia. Am J Surg Pathol 14: 524-537.
2. Noffsinger AE, Hart J, (2010) Serrated adenoma: a distinct form of non-polypoid colorectal neoplasia?. Gastrointest Endoscopy Clin N Am 20: 543-563.
3. Gurzu S, Jung I, (2012) Aberrant pattern of the cytokeratin 7/cytokeratin 20 immunophenotype in colorectal adenocarcinomas with BRAF mutations. Path Res Pract 208: 163-166.
4. Oka S, Tanaka S, Hiyama T, Ito M, Kitadai Y, et al. (2004) Clinicopathologic and endoscopic features of colorectal serrated adenoma: differences between polypoid and superficial types. Gastrointest Endosc 59: 213-219.
5. Jamarillo E, Tamura S, Mitomi H, (2005) Endoscopic appearance of serrated adenomas of the colon. Endoscopy 37: 254-260.
6. Jass JR, Whitehall VL, Young J, Leggett BA, (2002) Emerging concepts in colorectal neoplasia. Gastroentrology 123: 862-876.
7. Yang S, Farraye FA, Mack C, Posnik O, O'Brien MJ, (2004) BRAF and KRAS mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol 28: 1452-1459.
8. Jass JR, (2007) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50: 113-130.
9. Bayrak R, Haltas H, Yenidunya S, (2012) The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7/20+ phenotype is more specific than CDX2 antibody. Diagn Path 7: 9.
10. Janavicius R, Matiukaite D, Jakubauskas A, Griskevicius L, (2010) Microsatellite instability detection by High-Resolution Melting analysis. Clin Chem 56: 1750-1757.
11. Bayrak R, Yenidunya S, Haltas H, (2011) Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas. Path Res Pract 207: 156-160.
12. Saad RS, Silverman JF, Khalifa MA, Rowsel C, (2009) CDX2, cytokeratin 7 and 20 immunoreactivity in rectal adenocarcinoma. Appl Immunohistochem Mol Morphol 17: 196-201.
13. McGregor DK, Wu TT, Rashid A, Luthra R, Hamilton SR, (2004) Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability. Am J Surg Pathol 28: 712-718.
14. O'Brien MJ, Yang S, Mack C, Xu H, Huang CS, et al. (2006) Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma endpoints. Am J Surg Pathol 30: 1491-1501.
15. Stefanius K, Ylitalo L, Tuomiosto A, Kuivila R, Kantola T, et al. (2011) Frequent mutations of KRAS in adition to BRAF in colorectal serrated adenocarcinoma. Histopathology 58: 679-692.
16. Tatsumi N, Mukaisho K, Mitsufuji S, Tatsumi Y, Sugihara H, et al. (2005) Expression of cytokeratins 7 and 20 in serrated adenoma and related diseases. Dig Dis Sci 50: 1741-1746.
17. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, et al. (2009) KRAS and BRAF mutations in advanced colon cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from MRC FOCUS trial. J Clin Oncol 27: 5931-5937.
18. Garcia-Solano J, Perez-Guillermo M, Conesa-Zamora P, Acosta-Ortega J, Trujillo-Santos J, et al. (2010) Clinicopathologic study of 85 colorectal serrated adenocarcinomas: further insights into the full recognition of a new subset of colorectal carcinoma. Hum Pathol 41: 1359-1368.
19. Neumann J, Reu S, Kirchner T, (2012) Prognostic marker profiles for risk of distant metastases in colorectal cancer. Pathologe 33: 39-44.